Cumberland Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CPIX research report →
Price Chart
About the company
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets.
- CEO
- A. J. Kazimi
- IPO
- 2009
- Employees
- 88
- HQ
- Nashville, TN, US
Get TickerSpark's AI analysis on CPIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $104.58M
- P/E
- -9.77
- PEG
- 0.07
- P/S
- 3.34
- P/B
- 6.00
- EV/EBITDA
- -20.77
- Div Yield
- 21.49%
- Gross Margin
- 83.37%
- Op Margin
- -30.79%
- Net Margin
- -33.92%
- ROE
- -47.10%
- ROIC
- -34.15%
Latest fiscal year · YoY change
- Revenue
- $44.52M+17.6%
- Gross Profit
- $37.85M+21.0%
- Op Income
- $-2,791,993
- Net Income
- $-2,836,128+56.2%
- EPS
- $-0.19+58.7%
- OCF Growth
- +905.7%
- FCF Growth
- +710.5%
- 52W High
- $9.28
- 52W Low
- $1.85
- 50D MA
- $7.41
- 200D MA
- $5.33
- Beta
- 0.10
- RSI (14)
- 44
- Avg Volume
- 87.71K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the CPIX Q1 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 58.4%
- Shares Outstanding
- 14.98M
- Float Shares
- 8.75M
of shares held by institutions
34 13F filers
Buy/sell ratio 3.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ikarian Capital, LLC | 503.15K | ▼ 50.00K |
| Renaissance Technologies LLC | 478.26K | ▲ 7.57K |
| Vanguard Group Inc | 411.79K | 0 |
| Vanguard Capital Management LLC | 379.48K | ▲ 17.72K |
| Dimensional Fund Advisors LP | 233.31K | ▼ 43.05K |
| Boothbay Fund Management, LLC | 112.54K | ▼ 15.15K |
| Geode Capital Management, LLC | 108.41K | ▼ 5.88K |
| Perceptive Advisors LLC | 96.98K | ▼ 100.00K |
| Citadel Advisors LLC | 73.39K | ▲ 56.75K |
| Blackrock, Inc. | 63.55K | ▲ 6.66K |
| Bank Of New York Mellon Corp | 58.46K | 0 |
| Jane Street Group, LLC | 56.74K | ▲ 42.13K |
Held by 33 ETFs
Biggest fund positions in CPIX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Brown Martin S JR | other | 1,800 |
| Mar 18, 26 | Galante Joseph C | other | 1,800 |
| Mar 18, 26 | Jones James | other | 1,800 |
| Mar 18, 26 | Krogulski Kenneth | other | 4,000 |
| Mar 18, 26 | Krogulski Kenneth | other | 1,800 |
| Mar 18, 26 | Young Caroline | other | 1,800 |
| Mar 18, 26 | Anthony Todd M. | other | 3,000 |
| Mar 18, 26 | Bitterman Chris T. | other | 3,000 |
| Mar 18, 26 | Hamm John M. | other | 3,000 |
| Mar 18, 26 | Herman James L | other | 2,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CPIX coverage
Recent articles, reports, and earnings notes.
No research on CPIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CPIX report →Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Crosses Above 200 Day Moving Average – What’s Next?
defenseworld.net · Sep 24
Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)
defenseworld.net · Sep 11
Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity
seekingalpha.com · Aug 13
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?
defenseworld.net · Aug 12
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 4
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
marketbeat.com · Aug 4
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
prnewswire.com · Aug 4
Possible Generic Drug Tariffs and 2 Microcaps
zacks.com · Jul 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.